Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00005998 · Masonic Cancer Center, University of Minnesota · PHASE2 · withdrawn · last registry update 2017-11-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn because study never enrolled patients” | – | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-08-29Phase 3 first posted: ARCAGY/ GINECO GROUP, Niraparib + Niraparib + TSR-042 (Dostarlimab) (NCT03651206)
- 2018-05-23Phase 3 first posted: Children's Oncology Group, Carboplatin + Cisplatin (NCT03533582)
- 2017-06-09Phase 3 first posted: Astellas Pharma Inc, Gilteritinib + Cytarabine (NCT03182244)
- 2017-05-12Phase 3 first posted: Alliance for Clinical Trials in Oncology, Allopurinol + Cytarabine (NCT03150693)
- 2017-04-26Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Cytarabine (NCT00792948)
- 2017-04-17Results posted on the registry: SWOG Cancer Research Network, pegfilgrastim + AC regimen (NCT00070564)
- 2017-02-06Results posted on the registry: Alliance for Clinical Trials in Oncology, cytarabine + daunorubicin (NCT00651261)
- 2017-01-30Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Carboplatin (NCT03036488)
- 2017-01-09Phase 3 first posted: Beat AML, LLC, Samalizumab (BAML-16-001-S1) + BI 836858 (BAML-16-001-S2) (NCT03013998)
- 2017-01-02Phase 3 first posted: Children's Oncology Group, Calaspargase Pegol + Cyclophosphamide (NCT03007147)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision